GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeOne Medicines Ltd (HKSE:06160) » Definitions » Future 3-5Y Total Revenue Growth Rate

BeOne Medicines (HKSE:06160) Future 3-5Y Total Revenue Growth Rate : 18.38 (As of May. 30, 2025)


View and export this data going back to 2018. Start your Free Trial

What is BeOne Medicines Future 3-5Y Total Revenue Growth Rate?

Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, BeOne Medicines's Future 3-5Y Total Revenue Growth Rate is 18.38.


Competitive Comparison of BeOne Medicines's Future 3-5Y Total Revenue Growth Rate

For the Biotechnology subindustry, BeOne Medicines's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeOne Medicines's Future 3-5Y Total Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's Future 3-5Y Total Revenue Growth Rate falls into.


;
;

BeOne Medicines  (HKSE:06160) Future 3-5Y Total Revenue Growth Rate Explanation

Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.


BeOne Medicines Future 3-5Y Total Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of BeOne Medicines's Future 3-5Y Total Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


BeOne Medicines Business Description

Industry
Address
c/o BeOne Medicines I GmbH, Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
Executives
Baker Felix James 2201 Interest of corporation controlled by you
Baker Julian Charles 2201 Interest of corporation controlled by you
Baker Bros. Advisors (gp) Llc 2201 Interest of corporation controlled by you
Baker Brothers Life Sciences Capital, L.p. 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co. 2502 Approved lending agent
Oyler John Victor 2101 Beneficial owner
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd. 2102 Investment manager
Hhlr Fund, L.p. 2101 Beneficial owner
Amgen Inc. 2101 Beneficial owner
Hillhouse Capital Advisors, Ltd. 2102 Investment manager
Gaoling Fund, L.p. 2101 Beneficial owner
Fidelity Management & Research Company
Fmr Co., Inc.

BeOne Medicines Headlines

No Headlines